Avid Bioservices Inc (CDMO)

[freethemice]

In the table of phase III first-line NSCLC trials you can see that the Sandler et al trial (Avastin) and the
Scagliotti et al trial (motesanib) both increased the MOS by 2 months in the treatment arms.
In the Avastin case this increase was statistically significant (P = 0.003) and in the motesanib case
it was not (P = 0.14). Looking at the Kaplan-Meier curves gives an indication as to why this was so.

Sandler et al.

Scagliotti et al.

Motesanib is a "selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3;
platelet-derived growth factor receptor; and Kit", which makes it similar to sorafenib.